Evaluation of the effectiveness of the combination of doxycycline and trifarotene for managing acne vulgaris of moderate to severe severity: a study in a tertiary care hospital
DOI:
https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20240392Keywords:
AV, Oral antibiotics, Doxycycline, TrifaroteneAbstract
Background: Acne vulgaris (AV), affecting diverse skin types, prompts a uniform therapeutic approach, with options ranging from topical to systemic treatments. Trifarotene, a fourth-generation topical retinoid, offers precise skin-specific effects, especially in facial and truncal acne treatment. The study aimed to evaluate the effectiveness of the combination of doxycycline and trifarotene for managing AV of moderate to severe severity.
Methods: At Mymensingh medical college hospital, the study enrolled 100 individuals to evaluate a new treatment for moderate AV from Jan-Jun 2023. Treatment comprised oral doxycycline (100 mg) and topical trifarotene (0.005% w/w) over 2 months, following a stratified randomization process. Evaluation criteria included clinical scores, lesion counts, and safety parameters, analyzed using SPSS v20.
Results: Study on doxycycline and trifarotene for moderate to severe acne shows promising results. Participants, mainly aged 15-25 exhibit diverse demographics and balanced gender ratio. Significant improvement on investigator's global assessment (IGA) scale is noted, with 35% experiencing notable progress at 9-10 weeks, alongside reduction in Propionibacterium acnes growth and positive patient feedback with 36% reporting 'good' response.
Conclusions: The study on doxycycline and trifarotene for moderate acne exhibits robust methodology with adherence to established practices and stratified randomization. Results, assessed via IGA, demonstrate promising efficacy and safety, providing insights for diverse skin types' acne management enhancement.
Metrics
References
Taylor SC, Cook-Bolden F, Rahman Z, Strachan D. Acne vulgaris in skin of color. J Am Acad Dermatol. 2002;46(2):S98-106.
Bikowski J. Back in the spotlight: effective options for truncal acne Available at: http://practicaldermatology.com/2010/02/back-in-the-spotlight-effective-options-for-truncal-acne. Accessed on 17 January, 2023.
Del Rosso JQ. Management of truncal acne vulgaris: current perspectives on treatment. Cutis. 2006;77:285-9.
Liu CW, Tan J. Understanding truncal acne: a practical guide to diagnosis and management Available at: http://www.skintherapyletter.com/ conditions/acne/truncal-diagnosis-management/. Accessed on 17 January, 2023.
Tan J, Beissert S, Cook-Bolden F, et al. Impact of facial and truncal acne on quality of life: A multi-country population-based survey. J Am Acad Dermatol Int. 2021;3:102-10.
Czernielewski J, Michel S, Bouclier M, Baker M, Hensby C. Adapalene biochemistry and the evolution of a new topical retinoid for treatment of acne. J European Academy Dermatol Venereol. 2001;15:5-12.
Thiboutot D, Dreno B, Abanmi A. Practical management of acne for clinicians. An international consensus from the Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2018;78(2-1):S1-23.
Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay A, Leyden JJ et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003;49(1):S1-37.
Fanelli M, Kupperman E, Lautenbach E, Edelstein PH, Margolis DJ. Antibiotics, Acne, and Staphylococcus aureus Colonization. Arch Dermatol. 2011;147(8):917-21.
Del Rosso JQ. Oral doxycycline in the management of acne vulgaris: current perspectives on clinical use and recent findings with a new double-scored small tablet formulation. J Clin Aesthet Dermatol. 2015;8(5):19-26.
Zaenglein AL, Pathy AL, Schlosser BJ, Ali A, Hilary EB, Diane S et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945-73.e33.
Kolli SS, Pecone D, Pona A, Cline A, Feldman SR. Topical retinoids in acne vulgaris: a systematic review. Am J Clin Dermatol. 2019;20(3):345-65.
Thoreau E, Arlabosse JM, Bouix-Peter C, Sandrine C, Laurent C, Sébastien D t al. Structure-based design of trifarotene (CD5789), a potent and selective RARgamma agonist for the treatment of acne. Bioorg Med Chem Lett. 2018;28(10):1736-41.
Aubert J, Piwnica D, Bertino B, Blanchet-Réthoré S, Carlavan I, Déret S et al. Non-clinical and human pharmacology of the potent and selective topical RAR-g agonist trifarotene. Br J Dermatol. 2018;179:442-56.
Del Rosso JQ. Truncal acne vulgaris: the relative roles of topical and systemic antibiotic therapy. J Drugs Dermatol. 2007;6:148-51.
Tan J, Thiboutot D, Popp G, Melinda G, Charles L, James DR et al. Randomized phase 3 evaluation of trifarotene 50 mug/g cream treatment of moderate facial and truncal acne. J Am Acad Dermatol. 2019;80(6):1691-9.
Gold LS, Cruz A, Eichen_ eld L, Jerry T, Joseph J, Nabil K et al. Effective and safe combination therapy for severe acne vulgaris: a randomized, vehicle controlled, double-blind study of adapalene 0.1%-benzoyl peroxide 2.5%fixed-dose combination gel with doxycycline 100 mg. Cutis. 2010;85(2):94-104.
Alagheband SJ, Miller JJ, Clarke JT. Individualizing patient education for greater patient satisfaction. Cutis. 2015;95:291-2.
Torok HM, Pillai R. Safety and efficacy of micronized tretinoin gel (0.05%) in treating adolescent acne. J. Drugs Dermatol. 2011;10:647-52.
Alexis AF, Woolery-Lloyd H, Williams K. Racial/ethnic variations in acne: implications for treatment and skin care recommendations for acne patients with skin of color. J Drugs Dermatol. 2021;20(7):716-25.
See JA, Goh CL, Hayashi N, Suh DH, Casintahan FA. Optimizing the use of topical retinoids in Asian acne patients. J Dermatol. 2018;45(5):522-8.
Goh CL, Tang MB, Briantais P, Kaoukhov A, Soto P. Adapalene gel 0.1% is better tolerated than tretinoin gel 0.025% among healthy volunteers of various ethnic origins. J Dermatol Treat. 2009;20(5):282-8.
Downloads
Published
How to Cite
Issue
Section
